• Mashup Score: 2
    New EMN risk stratification model for NDMM - 3 year(s) ago

    Mattia D’Agostino, MD, University of Torino, Turin, Italy, gives a summary of the new risk stratification model, the R2-ISS, for…

    Source: VJHemOnc
    Categories: Hem/Onc News and Journals, Latest Headlines
    Tweet Tweets with this article
    • Profile photo of VJHemOnc
      VJHemOnc

      New EMN risk stratification model for NDMM Mattia D’Agostino outlines the R2-ISS model for newly diagnosed #MultipleMyeloma: https://t.co/HRZU7Sj9CY #EMN #EMN21#HemOnc #Myeloma #MMSM #Camoldx

  • Mashup Score: 2
    DREAMM-2: update on belantamab mafodotin in R/R myeloma - 3 year(s) ago

    Sagar Lonial, MD, Winship Cancer Institute of Emory University, Atlanta, GA, outlines the findings of longer-term follow-up of the DREAMM-2…

    Source: VJHemOnc
    Categories: Hem/Onc News and Journals, Latest Headlines
    Tweet Tweets with this article
    • Profile photo of VJHemOnc
      VJHemOnc

      DREAMM-2: update on belantamab mafodotin in R/R #Myeloma @SagarLonialMD shares longer-term follow-up results: https://t.co/VjIiYIFOCm @EmoryMedicine @EmoryUniversity @WinshipAtEmory #EMN #EMN21 #HemOnc #MultipleMyeloma #MMSM #CTSM #TrialUpdate #ImmunoOnc

  • Mashup Score: 3
    Early SMM intervention may curtail progression - 3 year(s) ago

    With several Phase III trials suggesting early intervention in smoldering multiple myeloma (SMM) is beneficial, this precursor stage of multiple…

    Source: VJHemOnc
    Categories: Hem/Onc News and Journals, Latest Headlines
    Tweet Tweets with this article
    • Profile photo of VJHemOnc
      VJHemOnc

      Early smoldering #MultipleMyeloma intervention may curtail progression. Learn more about the regimens being investigated for early SMM intervention, w/ @SagarLonialMD from @WinshipAtEmory: https://t.co/u6fU4lpOGM #EMN #EMN21#HemOnc #Myeloma #MMSM

  • Mashup Score: 0
    Treating transplant-eligible myeloma: the future gold standard? - 3 year(s) ago

    Michele Cavo, MD, PhD, Bologna University School of Medicine, Bologna, Italy, discusses the latest developments in the treatment of multiple…

    Source: VJHemOnc
    Categories: Hem/Onc News and Journals, Latest Headlines
    Tweet Tweets with this article
    • Profile photo of VJHemOnc
      VJHemOnc

      Treating transplant-eligible #Myeloma: the future gold standard? Hear from Michele Cavo (@UniboMagazine) on the latest #MultipleMyeloma developments: https://t.co/0U3iSMcs7r #EMN #EMN21 #HemOnc #MMSM #MyelomaACTIONmonth #IAMRESILIENT2021 #mmMRD #CTSM #TrialUpdate

  • Mashup Score: 0
    Response monitoring in late-stage multiple myeloma - 3 year(s) ago

    Heinz Ludwig, MD, Wilhelminen Cancer Research Institute, Wilhelminenspital, Vienna, Austria, gives an overview of his presentation on response monitoring in…

    Source: VJHemOnc
    Categories: Hem/Onc News and Journals, Latest Headlines
    Tweet Tweets with this article
    • Profile photo of VJHemOnc
      VJHemOnc

      Response monitoring in late-stage #MultipleMyeloma Heinz Ludwig discusses the challenges of response monitoring using paraprotein production: https://t.co/VQWiJuNYWm #EMN #EMN21 #HemOnc #Myeloma #MMSM #MyelomaACTIONmonth #IAMRESILIENT2021

  • Mashup Score: 1
    Unravelling drug resistance and sensitization - 3 year(s) ago

    Michel Delforge, MD, PhD, University of Leuven, Leuven, Belgium, provides a summary of his EMN presentation, which focused on unraveling…

    Source: VJHemOnc
    Categories: Hem/Onc News and Journals, Latest Headlines
    Tweet Tweets with this article
    • Profile photo of VJHemOnc
      VJHemOnc

      Unravelling drug resistance and sensitization using genome-wide CRISPR-Cas9 knockout screening, w/ Michel Delforge from @LeuvenU: https://t.co/FG6AHuTHo6 #EMN #EMN21 #HemOnc #MultipleMyeloma #Myeloma #MMSM #MyelomaACTIONmonth #IAMRESILIENT2021

Load More